论文部分内容阅读
目的:探讨肝脾肾同治的组方降糖消渴颗粒对糖尿病(DM)大鼠血糖及骨骼肌AMPK信号通路的影响。方法:SD大鼠高脂饲料喂养4周后结合腹腔注射链脲佐菌素(STZ)30 mg·kg~(-1),建立2型糖尿病大鼠模型,将成模的大鼠按血糖随机分为模型组、阳性对照组(吡格列酮片1.5 mg/kg BW)、降糖消渴颗粒组(9 g生药/kg BW),并设正常对照组。干预前及干预2周、4周后,分别检测大鼠空腹血糖(FBS),实验结束后实时荧光定量PCR法检测大鼠肌肉组织AMPKα、葡萄糖转运子4(GLUT4)、胰岛素受体底物1(IRS-1)mRNA表达,Western Blot法检测AMPKα、p-AMPKα、GLUT4、IRS-1蛋白表达。结果:降糖消渴颗粒组大鼠空腹血糖水平均明显低于模型组大鼠(P<0.05),且该效果存在时-效关系。降糖消渴颗粒能上调DM大鼠骨骼肌组织AMPKαmRNA及蛋白表达,且p-AMPK蛋白量亦明显增加(P<0.01),同时提高DM大鼠骨骼肌组织GLUT4、IRS-1 mRNA及蛋白表达量(P<0.01)。结论:立足于肝脾肾三脏同治的中药复方降糖消渴颗粒能通过激活骨骼肌AMPK信号通路相关蛋白,达到改善DM大鼠糖代谢,提高骨骼肌胰岛素敏感性的作用。
Objective: To investigate the effect of the compound prescription of tonifying kidney and spleen and kidney on the blood glucose of diabetic rats and AMPK signal pathway of skeletal muscle. Methods: The rats of type 2 diabetes were established by injecting streptozotocin (STZ) 30 mg · kg -1 after 4 weeks of high fat diet in SD rats. The model group, positive control group (pioglitazone tablets 1.5 mg / kg BW), Jiangtangxueke granule group (9 g crude drug / kg BW), and set the normal control group. Fasting blood glucose (FBS) was measured in rats before and 2 weeks and 4 weeks after the intervention, respectively. The levels of AMPKα, GLUT4, insulin receptor substrate 1 (IRS-1) mRNA expression. The protein expression of AMPKα, p-AMPKα, GLUT4 and IRS-1 were detected by Western Blot. Results: The fasting blood glucose level of Jiangtangxiaoke Granule group was significantly lower than that of model group (P <0.05), and the effect had a time-effect relationship. Jiangtang Xiaoke Granule can up-regulate the mRNA and protein expression of AMPKα in skeletal muscle of DM rats, and also increase the protein level of p-AMPK (P <0.01) and increase the mRNA and protein expression of GLUT4, IRS-1 in skeletal muscle of DM rats Amount (P <0.01). Conclusion: Based on the three traditional Chinese medicines of the liver, spleen and kidney, the Chinese medicine compound Hypoglycemic and Diabetes-Reducing Granule can improve the glycometabolism and the insulin sensitivity of skeletal muscle by activating the AMPK signaling pathway-related proteins in the skeletal muscle.